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M.E. Lacouture et alS2recurrent glioblastoma (rGB), response rates to
systemic therapies are typically less than 10%, and
the progression-free survival (PFS) at 6 and 12
months are 15% and 6%, respectively.8 The median
overall survival (OS) of these patients with salvage
chemotherapy is 5.8 months with a 1-year survival
rate of just 21%.8 rGB patients who are surgical
candidates have a median OS of only 4.6 months if
left untreated.9 Furthermore, although treatment
with the vascular endothelial growth factor (VEGF)
inhibitor, bevacizumab, results in a high radiographic
response rate and prolonged PFS, there are no
randomized data that demonstrate an increase in
OS.10,11 In fact, recent data have shown that in newly
diagnosed GB patients, bevacizumab does not incre-
ase OS. Thus, there is a clear need for new and inno-
vative approaches for the treatment of rGB.Figure 1. The NovoTTF-100A System. (A) NovoTTF-
100A System with battery-operated ﬁeld-generating
device, connected transducer array (patient wears
4 arrays), and included backpack for portability. (B) The
NovoTTF-100A System as worn during therapy.The NovoTTF-100A System
The NovoTTF-100A System (Novocure Inc., Ports-
mouth, NH) is a novel anti-mitotic device that
delivers alternating electric fields (tumor-treating
fields, TTFields), and is approved by the US Food
and Drug Administration (FDA) and has a European
Conformity (CE) mark in Europe for use as mono-
therapy for the treatment of rGB.12 The basis of the
approvals was a phase III study (EF-11) comparing
NovoTTF Therapy to active standard chemotherapy
in rGB patients.13 The NovoTTF-100A System has
been commercially available by prescription since
2011 in the United States.
The NovoTTF-100A System consists of four trans-
ducer arrays, a connector cable, a field-generating
device, and a power source (battery or electrical
outlet). Treatment parameters are preset (200 kHz
and a minimal field intensity of 0.7 V/cm in the
brain); thus, there are no electrical adjustments
made by the patient or healthcare provider. TTFields
are delivered through non-invasive insulated trans-
ducer arrays that are applied to the shaved scalp
(Figure 1). The location of the arrays on the scalp is
calculated using a simulation software (NovoTAL™,
Novocure Inc.) that optimizes the field intensity
within a patient’s tumor based on head size and
tumor location.
Transducer arrays are supplied to patients in
individual sterile packages to minimize the risk of
infection, although the application of the arrays to
the scalp is not a sterile procedure. The arrays are
composed of insulated ceramic discs (nine per
array). The ceramic discs (with a high dielectric
constant) are biocompatible and are soldered to a
flexible circuit board (Figure 2). The ceramic discs
do not come into direct contact with the skin as they
are separated from the skin by a layer of conductive
hydrogel (similar to that found on electrocardiogrampads). There is no direct electron transfer to the
skin; ion concentration changes in cells do not
occur, nor does electrolysis.14 The ceramic discs,
hydrogel, and circuitry are all attached to a hypo-
allergenic medical adhesive bandage to keep the
arrays in place on the scalp and in continuous direct
contact with the skin. A single plastic-coated wire
Figure 2. The NovoTTF-100A System Transducer Array.
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cable, which is attached to the field-generating
portion of the device. Although patients have
described a “warm sensation” during normal oper-
ation of the device, each array has eight temperature
sensors (thermistors) that continuously monitor tem-
perature. If the array temperature exceeds 41oC
(105.8oF), which is below the threshold for a
thermal skin burn,15 the device will shut off and
sound an alarm. The NovoTTF-100A System meets all
FDA medical electrical equipment and biocompati-
bility standards.16
NovoTTF-100A Therapy is administered by affixing
two pairs of orthogonally positioned transducer
arrays to the shaved scalp. Adequate shaving of the
scalp is required for optimum array-to-skin contact.
The arrays are worn continuously for 3–4 days before
removal for hygienic care of the scalp, re-shaving of
hair, and reapplication with new sets of arrays.Mechanism of Action of the NovoTTF-100A
System
While electric fields (at differing frequencies and
intensities) have been used in medicine for many
decades, it is only within the past decade that the
biological effect of alternating electric fields at inter-
mediate frequencies (100–300 kHz), and low intensity
(1–3 V/cm), has been realized. Evaluation of these
intermediate-frequency, alternating electric fields in
multiple cancer cell lines has demonstrated an anti-
mitotic effect that is both frequency-specific and
intensity-specific in cancer cells, with no effect on
non-mitotically active cells.14,17 TTFields interfere
with cancer cell division during three phases of
mitosis: (1) metaphase, with inhibition of microtubule
spindle assembly; (2) anaphase, with cytoplasmic
blebbing and asymmetric chromosomal segregation;and (3) telophase, with a dielectrophoretic effect,
resulting in an inability of the organelles and macro-
molecules to segregate within the daughter cells due
to the formation of a nonuniform field gradient.18–21
TTFields do not cause cell membrane depolarization
and thus do not stimulate nerves or muscles, nor do
they cause thermal heating of tissues.22 The current
FDA-approved frequency and intensity settings for the
NovoTTF-100A System are optimized for the treat-
ment of rGB.Pivotal Phase III Study (EF-11)
A phase III randomized trial (EF-11) was con-
ducted based on encouraging evidence of TTFields
activity in glioma animal models and subsequent
pilot data in patients with newly diagnosed and
recurrent glioblastoma demonstrating safety, feasibil-
ity, and promising efficacy.13,14 This trial compared
NovoTTF Therapy to active chemotherapy (based on
physicians choice) in patients with rGB.13 Patient
characteristics were well balanced between the
treatment arms of the trial, median age was 54 years,
19% of patients had previously been treated with
bevacizumab, and 90% were at their second or later
recurrence. Patients were randomized to NovoTTF
Therapy alone (n ¼ 120) or chemotherapy (n ¼
117), with patients in the active chemotherapy
treatment arm receiving either a single agent or a
combination containing bevacizumab (31%), irinote-
can (31%), nitrosoureas (25%), carboplatin (13%),
temozolomide (11%), or other agents (5%).
The primary endpoint of the trial was OS.
NovoTTF Therapy demonstrated comparable OS to
active chemotherapy, with a median OS of 6.6 versus
6.0 months, respectively (hazard ratio ¼ 0.86 [95%
confidence interval [CI], 0.66–1.12]; P ¼ .27). The
PFS6 (PFS rate at 6 months) was 21.4% versus 15.1%
M.E. Lacouture et alS4(hazard ratio 0.81 [95% CI, 0.60-1.09]; P ¼ .13), and
the overall response rate was 14.0% versus 9.6% (P ¼
0.19) for NovoTTF Therapy compared to active
chemotherapy, respectively. The safety analyses
favored NovoTTF Therapy, with severe adverse
events occurring in 6% and 16% (P ¼ .022) of
patients treated with NovoTTF Therapy and active
chemotherapy, respectively.13
In the phase III trial, the median adherence to
NovoTTF Therapy was 86% (range, 41%–98%) of the
time (n ¼ 116), measured by a log file in the device
that records time on therapy. This translated into a
mean use of 20.6 hours per day. In the NovoTTF
Therapy group, 93 (78%) patients completed 4 weeks
of therapy (one cycle), with 27 (23%) discontinuing
treatment within cycle 1, due to non-adherence or
inability to handle the device.13 Adherence with
NovoTTF Therapy was the main predictor of
improved OS in this trial, with patients who used
the device for more than 18 hours a day living
significantly longer than those who used it for less
than 18 hours a day (7.8 months v 4.5 months,
Po.05, respectively).12 The most common device-
related adverse events were grade 1 and 2 dermato-
logic adverse events (dAEs) of the scalp beneath the
arrays, occurring in 18 patients or 16% (all grades;
2% grade 2) and no grade 3 or 4 dAEs. Skin ulcer-
ation was observed in one patient (o1%). All dAEs
were reversible and did not result in discontinuation
of patients from study. Other device-related AEs
included headache (3%), malaise (2%), muscle
twitching (1%), and fall (1%). Systemic toxicities
including grade 3/4 hematologic (17%), gastrointes-
tinal (17%), and infections (8% of patients) were
significantly more frequent in chemotherapy-treated
patients, compared to 3%, 4%, and 4%, respectively,
for patients receiving NovoTTF Therapy (Po.05;
Fisher exact test).13
Quality-of-life was analyzed in patients who
remained on therapy for43 months and for whom
quality-of-life data were available (n ¼ 63, 27%).
Whereas no differences in global health and social
functioning between NovoTTF Therapy and active
chemotherapy were observed, cognitive, social, role,
and emotional functioning were all higher in the
NovoTTF Therapy-treated group, while their phys-
ical functioning was slightly worse when compared
to the chemotherapy treatment group. Symptoms
that were reported by patients to be more severe
with chemotherapy than with NovoTTF Therapy
included appetite loss, diarrhea, constipation, nau-
sea/vomiting, pain, and fatigue.13
Because the dAEs observed with NovoTTF Therapy
are unique to this novel oncologic treatment modal-
ity, and treatment continuity is critical for better
response to therapy, there is a need for im-
proved nomenclature, preventive and managementstrategies, and the identification of risk factors. In
addition, the current Common Terminology Criteria
for Adverse Events (CTCAE) version 4.0 grading
criteria for the skin and subcutaneous tissue disor-
ders; injury, poisoning and procedural complications;
and infections and infestations system organ classes
do not adequately describe or characterize the dAEs
seen with NovoTTF Therapy.23–25 Efforts to improve
the nosology will help communication between
healthcare providers and will also improve the
description and grading of these dAEs in current
and future clinical trials. Similarly, the development
of management strategies for dAEs will help maintain
patient quality-of-life and adherence to NovoTTF
Therapy.BASIC PATHOPHYSIOLOGY OF SKIN AND
HAIR
In order to understand pathogenic mechanisms
underlying dAEs and to develop effective interven-
tions, it is important to recognize that the skin is a
complex, mitotically active, multi-layered organ com-
posed of multiple cell types with various functions.26
Structurally, the skin is composed of three layers:
(1) the epidermis, which functions as a permeability
and protective barrier and as an organ for immune
surveillance; (2) the dermis, which provides the
structural support to the skin and contains an
extensive lymphatic and neurovascular network;
and (3) the hypodermis and the associated subcuta-
neous fat, both of which provide insulation and
contain blood vessels and nerves (Figure 3). All three
of these layers function together to form a physical
permeability barrier that protects the body from
pathogenic microbes and ultraviolet radiation, regu-
lates temperature, allows for the transduction of
sensations, repairs wounds, and contributes to an
individual’s physical appearance and sense of self.27
Although the epidermis and its outer stratum cor-
neum provide the initial physical barrier to the
environment, the structural integrity of skin as a
whole is supported primarily by the dermis and
hypodermis.28
The epidermis is the outermost layer of the skin. It
is the only skin layer in direct contact with the
hydrogel covering the ceramic discs and the adhesive
tape of the bandage holding the transducer arrays in
position. The epidermis is a continually renewing
structure that gives rise to appendages such as
pilosebaceous units (hair follicles), nails, and sweat
glands. Epidermal appendages also provide special
protective or sensory functions. The epidermis ranges
in thickness from 50 mm to 1.5 mm, as compared with
the 1.5- to 4.0-mm thickness of the dermis.29 More
than 80% of cells in the epidermis are keratinocytes.
Figure 3. Schematic representation of human skin struc-
ture and cell population. The skin comprises three main
layers: the epidermis, dermis, and hypodermis. The resi-
dent cell populations and various structures present
throughout the skin allow for maintenance of an efﬁcient
barrier against water loss and protection against threats
such as ultraviolet radiation (UVR) and microbial patho-
gens. The blood and lymph vessels allow for the migra-
tion of immune cells in and out of the skin, so that the
cell population of the skin is constantly in a state of ﬂux,
in response to the demands of the cutaneous inﬂamma-
tory and immune systems. Reprinted by permission from
Macmillan Publishers Ltd: Nature (MacNeil S. Progress
and opportunities for tissue-engineered skin. Nature.
2007;445:874-80), copyright 2007.
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cytes is 24 hours, and the transit time for a keratino-
cyte in the basal layer, from the time it loses contact
with the basal layer to the time it enters the stratum
corneum (outermost layer in the epidermis), is at least
14 days.30 Transit through the stratum corneum and
subsequent desquamation require another 14 days.30
Intercalated among the keratinocytes at different
levels are other cells—melanocytes, Langerhans cells,
and Merkel cells. Additional cells, including lympho-
cytes, are temporary residents of the epidermis and
are rare in normal skin. The innate immune system of
the skin, which comprises antigen-presenting cells
and circulating immune cells, provides additional
antimicrobial functions.
Pathologic changes in the skin exposed to
NovoTTF Therapy can occur or become exacerbated
as a result of a number of different stimuli. These
include repetitive mechanical trauma (as in the
application and removal of the arrays31 or shaving32)
resulting in erosions, inflammation (from the hydro-
gel covering the ceramic discs or adhesive33 or
moisture from ecrine sweat or ambient humidity34),
infection (as in bacterial folliculitis or impetigo35),
wound healing (surgical scars or delayed healing
associated with the use of bevacizumab36,37), andultraviolet (UV) radiation damage resulting in atro-
phy and actinic keratoses.38
Erosions are moist, circumscribed, depressed
lesions that result from loss of a portion or all of
the viable epidermis, with mild bleeding and asso-
ciated with pain or burning.39 Erosions may result
from trauma related to the repeated removal of the
arrays or shaving, inflammation and maceration from
sweat-derived moisture, rupture of vesicles or bullae
from infection, or epidermal necrosis from altered
perfusion due to pressure of the arrays. In general,
erosions do not result in a scar unless they become
secondarily infected.
Dermatitis is a nonspecific term denoting skin
inflammation, presenting with edema and erythema,
followed by scaling. With NovoTTF Therapy, two
types of dermatitis may develop. The first, represent-
ing approximately 20% of new cases of contact
dermatitis, is allergic contact dermatitis (ACD), a
cutaneous inflammatory reaction caused by contact
with a specific exogenous allergen to which a
person has been sensitized.40 The second is irritant
contact dermatitis (ICD), a nonspecific inflammation
of the skin in response to direct chemical damage to
epidermal cells and the release of inflammatory
chemokines. These two types of dermatitis have
unique clinical and pathophysiological characteris-
tics. In ACD, following contact with an allergen
(more than 3,700 chemicals have been identified as
culprits of ACD41), the skin reacts with inflammation
and the severity of the dermatitis can range from
mild and temporary to severe and persistent. In the
latter case, the dermatitis may not resolve unless
treated, even if the offending allergen has been
withdrawn. When ACD is suspected, allergen iden-
tification through epicutaneous patch testing has
been demonstrated to improve quality-of-life,42 as it
allows for identification of the condition and avoid-
ance of the causal allergen. In oncology patients,
patch testing may not always be feasible due to the
frequency of visits necessary (usually four) and
concomitant medications that hinder the interpreta-
tion of patch testing (ie, corticosteroids, immuno-
suppressants). In these cases, a provocative use test
(PUT) may identify the culprit in some cases.43
In ACD, the symptoms will not resolve unless the
offending agent is removed and the area is treated
with a topical corticosteroid, while ICD will resolve
a few days after the culprit is removed. As noted
above, ICD is a nonspecific inflammation of the skin
manifested by erythema, edema, pruritus or burning,
and scaling as a response to direct chemical dam-
age.44 Thus, in ICD, removal of the culprit is the only
treatment necessary.
A more severe dAE is an ulcer, a lesion in which
the epidermis and the dermis have been destroyed.
Ulcers are usually round and their borders are well
M.E. Lacouture et alS6defined. The base of an ulcer may be clean or
necrotic and may contain granulation tissue. A dis-
charge is usually indicative of infection and may be
purulent, granular, or malodorous. Surrounding skin
may be altered. During healing, the ulcer will form a
crust composed of dried serum, blood, or exudate.
The color of the crust is important: yellow-brown
from a dried serous secretion; yellowish-green from a
purulent secretion; and reddish-black from a hemor-
rhagic secretion. Ulcers may result in scarring.
Infections are common in skin and soft tissues
given the abundance of microbes present in these
structures.45 A pustule is a circumscribed, raised
lesion in the epidermis containing pus. Pus is com-
posed of leukocytes and cellular debris (yellow color)
and may contain bacteria (greenish-yellow color) or
be sterile (white color). Pustules may contain a hair at
the center, may vary in size, and may coalesce to
form plaques of pus. Pustules may be confused with
vesicles and bullae, which are fluid-filled lesions that
are not always infected. Friction vesicles or bullae
with clear contents may occur with shear forces on
the epidermis or initially with viral infections,
whereas those resulting from bacterial infections or
late-stage viral infections will have yellow-greenish
contents. In cases of bacterial infections resulting in
bullae, the term “bullous impetigo” is used.
Scars arise from fibrous tissue proliferations that
replace previously normal skin after a wound or
ulceration disrupts the integrity of the skin. Surgical
scars may retain a deeper pink or red color for months
after a surgical procedure, and hairs are usually absent.
The blood flow in scars is altered due to excess fibrous
tissue deposition, making them susceptible to dAEs
with NovoTTF Therapy use when the ceramic discs
are placed immediately over them. Similarly, skin
scarring, in the form of atrophy and absence of hair
follicles, may develop after radiation therapy and may
place these areas at higher risk for dAEs.
The use of NovoTTF Therapy involves placement
of the transducer arrays directly onto the scalp for at
least 18 hours a day. The arrays are left in place for
3–4 days before they are replaced with new arrays
that are relocated on the scalp, the latter practice
serves to minimize direct contact over the same
areas of skin. Prolonged contact with the arrays
poses unique chemical, mechanical, moisture, and
thermal-related stresses on skin which may account
for the development of dAEs. Consequently, contin-
uous application of the transducer arrays without
timely exchanges may cause the development of
distinct dAEs on the scalp characterized by inflam-
mation and, in some cases, associated with erosions,
ulcers, and secondary infections.
The quality of the array-to-scalp contact is negatively
affected by hair growth. The scalp contains approxi-
mately 100,000 hair follicles. These hair follicles are partof pilosebaecous units, which contain hair shaft-forming
cells, sebaceous glands, and arrector pili muscles.
During hair growth, the preceding hair shaft is pushed
up and out by a new shaft and results in shedding
(normally, approximately 100 strands of hair are shed
from the scalp every day).46 Hair grows approximately
5–12.5 mm every month or 0.2–0.5 mm per day, which
results in outward pressure on the adhered transducer
arrays and requires repeated shaving at every array
replacement (every 3–4 days). This is because an
increased distance between the arrays and skin will
allow an air gap to form, with air being an insulator for
electric fields, and will affect the delivery of TTFields.CHARACTERIZATION OF DERMATOLOGIC
ADVERSE EVENTS
In order to characterize the dAEs, data from
patients using NovoTTF Therapy were analyzed with
a focus on skin-related AEs (including photographs
of the scalp reviewed by a dermatologist) from the
completed phase III trial (EF-11) of NovoTTF Ther-
apy (n ¼ 116 patients),13 as well as from those
patients with AEs submitted in the post-marketing
surveillance program (n ¼ 570 patients). The
ongoing phase IV post-approval study in rGB (EF-
19; NCT01756729) has not had sufficient enrollment
at present to further define dAEs adequately.
Types of dermatologic adverse events were char-
acterized, and associated patient data (if available)
were reviewed, including time to development of
dAE, clinical presentation, risk factors, and manage-
ment strategies employed.
In the phase III trial (EF-11) 16% of patients (18 of
116 patients) had grade 1 or 2 dAEs and there was a
1% incidence of skin ulcer (1 of 116 patients). There
were no grade 3 or 4 dAEs. Time to dAE onset was
2–6 weeks. These events were graded according the
CTCAE version 3.0. However, this version of the
CTCAE did not allow for adequate characterization
of the dAEs seen with NovoTTF Therapy. As a result,
all dAEs were grouped into the same category.
Although the information available from the post-
marketing surveillance program does not allow for
detailed grading, 21.8% of patients (156 of 570
patients) had non-serious dAEs, with some patients
reporting more than one event. There was a 0.7%
incidence of skin ulcer (4 of 570 patients). The
median time to dAE onset was 32.5 days (range of 2–
520 days). Patients in this setting have reported the
need for treatment interruptions or discontinuation
of NovoTTF Therapy due to dAEs, but the exact
percentage is not known because the post-marketing
program is a “self report” program. This latter issue
highlights the need for dermatologic management
guidelines when NovoTTF Therapy is utilized in
Table 1. Types and Potential Causes of
Dermatologic Adverse Events
Adverse Event Potential Cause
Irritant contact
dermatitis
Chemical irritation from
hydrogel, moisture, and/or
alcohol
Allergic contact
dermatitis
Allergy to tape and/or
hydrogel
Erosion Mechanical trauma from
shaving and/or array
pressure/removal
Ulcer Decreased perfusion from
array pressure (especially in
areas overlying scars/
hardware/prior radiation)
Skin infection/
pustules
Secondary bacterial infection
Figure 4. Contact dermatitis (may or may not be symp-
tomatic). (A) Erythema from scalp irritation that was
caused by the adhesive tapes or hydrogel. The allergic
dermatitis resolved with the application of a topical
corticosteroid. (60-year-old man who had been on temo-
zolomide and NovoTTF Therapy for 7 months). (B) Irritant
reaction on the right side of scalp with erythema corre-
sponding to the three strips of hydrogel on the transducer
arrays. This adverse event occurred during the hottest days
in the summer and was a result of a combination of high
ambient temperature, increased humidity, excessive sweat-
ing, and patient sleeping on the right side of her head.
Treatment required 1-2 weeks of device interruption and
use of a topical corticosteroid (65-year-old woman who
had been on NovoTTF Therapy for 2 months).
NovoTTF-100A System for recurrent glioblastoma S7clinical practice outside of the carefully managed
setting of a clinical trial.
A review of scalp photographs from patients on
the EF-11 trial and from the post-marketing program
(when available) by a dermatologist (M.E.L) allowed
for the characterization of these dAEs. The clinical
presentation of dAEs associated with NovoTTF Ther-
apy can be divided into four major categories:
dermatitis (allergic or irritant), erosion, infection,
and ulcer (Table 1 and Figures 4–7).
In addition to the above findings, a review of
patient data identified the following risk factors that
may be associated with NovoTTF Therapy dAEs:
(1) placement of ceramic disc(s) from the transducer
arrays on the scalp overlying scars or craniotomy
hardware; (2) history of contact dermatitis to materials
used in the composition of array skin contact materials
(ie, tape adhesive or hydrogel); (3) hyperhidrosis
(excessive sweating) from hot, humid weather, fever,
or occlusive wigs; (4) previous skin exposure to UV or
ionizing radiation; (5) high doses or recent change in
systemic corticosteroids; or (6) concurrent administra-
tion of systemic anticancer agent (eg, chemotherapeu-
tics, biologics, or targeted therapeutics).
MANAGEMENT OF DERMATOLOGIC
ADVERSE EVENTS
The management of the dAEs associated with
NovoTTF Therapy can be divided into prophylactic
and treatment interventions.
Prophylactic Interventions
Based on the clinical trial and post-marketing expe-
rience to date with NovoTTF Therapy, prophylactic
interventions that decrease the risk of dAEs are divided
into five categories: (1) patient and caregivereducation, (2) scalp preparation, (3) infection preven-
tion, (4) avoidance of scars and craniotomy hardware,
and (5) array relocation. Table 2 provides a summary of
these practices for use by the patient or caregiver.
Patient and Caregiver Education
Scalp preparation. This basic step is critical to
ensure good array-to-scalp contact, which will lower
the risk of skin irritation and optimize delivery of the
TTFields. Factors that are known to affect array-to-scalp
contact include hair length (determined by proper and
Figure 5. Dermatologic erosions and skin infection
(folliculitis) in a 60-year-old man who had been on
temozolomide and NovoTTF Therapy for 3 months.
Figure 6. Skin infection/folliculitis. (A) Folliculitis (62-
year-old man after receiving NovoTTF Therapy for
4 weeks). (B) Skin infection (41-year-old woman after
receiving NovoTTF Therapy for 3.5 weeks).
M.E. Lacouture et alS8timely shaving), moisture from sweat (determined by
eccrine sweating on the scalp), the presence of sebum
or the degree of “oiliness” of the scalp (determined by
individual patient skin characteristics and removal prior
to array placement), and the duration of skin contact
with the same set of arrays.
For removing hair from the scalp, an electric razor is
recommended because it offers a smaller risk of cuts as
compared to a straight blade razor. However, in some
patients, the use of an electric razor may actually lead
to an increase in folliculitis due to the pulling and
tension exerted on the hair while it is being cut. If this
is the case, patients may use a straight blade razor
while great care is taken to avoid skin cuts. The
closeness of the shave can be tested by running a
piece of gauze or a cotton ball, wet with 70% isopropyl
alcohol, across the shaved scalp. If there is detectable
friction or resistance, a closer shave is required.
After shaving, washing the scalp with a mild,
fragrance-free shampoo (eg, baby shampoo) will
remove some of the sebum of the skin that can
interfere with array-to-scalp contact. Dandruff sham-
poos (which contain pyrithione zinc) also can be
used and may offer additional benefit because they
have antimicrobial properties. Finally, wiping the
skin with 70% isopropyl alcohol will help to remove
the naturally occurring scalp sebum, resulting in
better contact of the arrays to the scalp. When using
alcohol, it is important to avoid contact with areas of
dermatitis, erosions, or ulcers, as the alcohol may
further irritate the skin.
On subsequent applications of the arrays, use of
mineral oil before shaving is recommended because
the oil can remove adhesive residues from the prior
set of arrays. This will allow for adequate cleansing
of the scalp and prevent the accumulation of bac-
teria and scaly skin.Infection prevention. The arrays are provided in
individual sterile packages to minimize infection risk.
Patients and their caregivers are advised to wash
their hands prior to application and removal of the
transducer arrays. The scalp should be washed with
shampoo between array exchanges. The electric
Figure 7. Skin ulceration. Note how the arrays are
arranged around the site of the ulcer (61-year-old man
after receiving NovoTTF Therapy for 2 weeks).
Table 2. Preventive Strategies for Dermatologic Ad
Category Guidelin
Shaving and
preparation
of the scalp
● Proper hand washing prior to
● Take time shaving the scalp u
● Ensure a close shave prior to a
● Cleaning the electric razor afte
infection
● Wash scalp with fragrance-free
dermatitis shampoo can also b
(eg, pyrithione zinc 2%, ciclop
● Ensure scalp is completely dry
Use of isopropyl
(70%)
alcohol
● Use of ﬁrst aid antiseptic rubbi
application is a necessary step
in better adherence of the arr
● After shaving and before placi
cotton ball soaked in ﬁrst aid a
● Avoid areas of skin irritation, a
isopropyl alcohol) may further
Transducer array
exchanges
● Change arrays on a regular ba
● When removing the arrays, av
60 seconds to remove each ar
● Using mineral (baby) oil on the
adhesive tape easier and less i
● To remove leftover array adhe
(baby) oil or pour into hands
adhesive
● Pay close attention to the scal
nurse if there are signs of skin
information on how to treat th
area(s) on the scalp and sharin
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instructions for cleaning) on a regular basis and
should not be shared with others.
Transducer array application. Arrays are placed
on the scalp according to the transducer array layout
plan, which is based on head size measurements, tumor
size, and tumor location. The ceramic discs of the arrays
should not be placed directly over implanted craniotomy
closure hardware or surgical scars. Placement of the
ceramic disc over a screw or plate may lead to
subsequent skin breakdown, erosion, or ulceration.
Every time a set of arrays is changed (approxi-
mately every 3–4 days) the position of the arrays
should be shifted approximately 0.75 inches from the
last location, so that the hydrogel layer is between the
prior contact sites. The ceramic discs will leave a
slight indentation on the surface of the scalp, allowing
patients and caregivers to readily see where to
position the new set of arrays. On the next transducer
array exchange, arrays should be shifted back to theverse Events
e for Patient/Caregiver
preparing the scalp for array application
sing gentle but ﬁrm circular motions
pplying the arrays
r every shave is important to lessen the risk of skin
, mild shampoo (eg, baby shampoo); seborrheic
e used as it has antibacterial properties
irox 1%, ketoconazole 2%).
before applying a new set of arrays
ng alcohol (70% isopropyl alcohol) prior to array
to remove naturally occurring scalp oils, resulting
ays to the scalp
ng the arrays, wipe the scalp with a gauze or
ntiseptic rubbing alcohol (70% isopropyl alcohol)
s the ﬁrst aid antiseptic rubbing alcohol (70%
irritate the skin
sis (at least every 3-4 days)
oid “pulling” on the skin and take approximately
ray
edges of the array may make the removal of the
rritating to the skin
sive, use gauze or cotton ball soaked in mineral
and gently rub scalp in areas of remaining
p at each array exchange and notify the doctor/
irritation or open areas, in order to receive
e affected area(s). Taking a picture of the affected
g with doctor/nurse is advised
Figure 8. Preventive measures. Illustration of shifting transducer arrays at each array exchange.
M.E. Lacouture et alS10previous position. Shifting the arrays every time they
are changed will minimize continuous exposure of
the same portion of the scalp to the hydrogel that
may lead to subsequent dAEs (Figure 8).
Transducer array removal. Each set of arrays
should be exchanged at least every 3–4 days. More
frequent array exchanges may be required in some
patients. Careful removal of arrays (taking
approximately 60 seconds to remove each array)
will lessen irritation to the skin. When removing the
arrays from the scalp, excessive force should be
avoided. In addition, applying mineral oil to the
edges of the arrays may make removal easier and
less irritating to the skin. The use of mineral oil
(applied via a soaked gauze or cotton ball or directly
to the scalp by hand) will help to ensure complete
removal of array adhesive and minimize damage to
the skin. Forceful rubbing of the scalp to remove
array adhesive should be avoided.
Examination of the scalp at each array exchange
by patients and/or caregivers will allow for identi-
fication of asymptomatic dAEs and early intervention
after consultation with the health care provider.
Taking photographs of the affected area(s) on the
scalp to review with the physician or nurse in
subsequent office visits, or for more urgent consul-
tation and intervention, is recommended.
Additional considerations. Because the array
hydrogel is hydrophilic, it may become partially
liquified (glutinous) during warmer weather or after
intense physical activity because the hydrogel will
absorb sweat. This may necessitate more frequent
changes of the arrays (eg, every 1–2 days). Some
medications such as corticosteroids (after prolonged
use), systemic chemotherapies, and certain targeted
therapies (ie, vascular endothelial growth factor
[VEGF] inhibitors such as bevacizumab) may incre-
ase the risk of skin reaction or affect wound healing.
Ongoing clinical trials evaluating NovoTTF Therapy
in combination with other systemic therapies will
better define the safety of NovoTTF Therapy with
concurrent therapies. A recent presentation of datafrom a cohort of 20 patients treated with combined
NovoTTF Therapy and bevacizumab did not suggest
any concern regarding adverse events in general and
dAEs specifically.47
Treatment Interventions—Pharmacologic and
Treatment Interruption
The NovoTTF-100A System treatment parameters
(frequency and intensity), based on preclinical stud-
ies, are preset into the device; therefore, no “dose
modifications” can be made for the management of
adverse events. Thus, in addition to prophylactic
interventions, the primary options for treatment of
dAEs are based on the type of dAEs and include
topical therapies, relocation of arrays, and avoidance
of affected skin whenever possible. Although array
shifting to different scalp locations is a recom-
mended prophylactic measure, this can also be used
if there are existing sites of dAEs by shifting the
arrays around the existing injury sites (Figures 7 and
8). If the area of skin irritation is such that shifting
of the arrays is not feasible, the area(s) of skin irrita-
tion can be protected with sterile nonadherent dress-
ing pads (Figure 9), while avoiding placement of
the ceramic discs directly over these areas. Infre-
quently, oral antibiotics are required along with
treatment interruption for intolerable grade 2 or
grade 3 dAEs.
Pharmacologic Treatment
The primary treatments for NovoTTF Therapy-
related dAEs are topical corticosteroids and topical
antibiotics (Figure 10). If there are signs of dermatitis
(Table 1), a topical corticosteroid is recommended.
However, when the epidermal barrier is compro-
mised (erosions) or when there are signs of infection
(Table 3), topical antibiotics are recommended.
Obtaining bacterial skin cultures prior to initiating
antibiotic therapy is helpful to identify the causative
microorganism(s) and to ensure appropriate antimi-
crobial coverage.
Topical therapies may be applied only at the time
of transducer array exchanges (approximately every
Figure 9. Example of protection of sites of dermatologic
adverse events with small sterile nonstick gauze barriers.
(Note: gauze should not be directly beneath any of the
array ceramic disks.)
NovoTTF-100A System for recurrent glioblastoma S113–4 days); therefore, high-potency corticosteroid
ointments (eg, clobetasol 0.05%, betamethasone
0.05%) are recommended to maximize skin absorp-
tion and pharmacological action. Because creams
and ointments contain lipid ingredients, it is impor-
tant that any topical residue left on the skin be
removed with scalp washing or 70% isopropylSeverity
Type of Dermatologic Adverse Ev
Dermatitis Erosions 
Figure 10. Treatment algorithm for dermatologic adversealcohol as this residue will interfere with the adher-
ence of the arrays to the scalp and hence may affect
transmission of the TTFields. The use of topical or
oral antibiotics should be selected based on the
spectrum of activity for the skin flora on the scalp
(eg, mupirocin or polymyxin B/bacitracin for topical
preparations). Use of neomycin-containing topical
antibiotics is discouraged because of the relatively
high incidence of contact dermatitis in the general
population. It is recommended that topical therapies
are applied and left on the scalp for a minimum of
15–30 minutes before removing any residual cream/
ointment with 70% isopropyl alcohol or re-washing
of the scalp and reapplication and relocation of the
arrays.Treatment Interruptions
For intolerable grade 2 and grade 3 dAEs, treatment
interruption in conjunction with topical therapies is
recommended. It should be noted that reapplication
and relocation of the arrays is possible after treatment
interruptions due to intolerable grade 2 or grade
3 events. Anecdotal data suggest that interruption for
2–7 days is frequently sufficient for resolution of the
dAEs. This is consistent with the turnover rate of cells
in the epidermis as described previously. Patients with
prior dAEs may be more likely to have a recurrence ofent and Recommended Interventions 
Infections Ulceration 
events associated with the use of NovoTTF Therapy.
Table 3. Signs of Skin Events Based on Underlying Pathogenesis
Dermatitis Skin Infection Mechanical Ischemia
Erythema Erythema Erosions Ulcers
Scaling Discharge Abrasions Pain
Erosions Pustules Lacerations
Edema Pain Pain/burning
Pruritus Yellow/green crusting
M.E. Lacouture et alS12dAEs once the arrays are reapplied, so patient educa-
tion and use of prophylactic measures upon rechal-
lenge are recommended.
Duration of treatment interruptions should be
minimized, as treatment adherence is correlated
with NovoTTF Therapy efficacy. A post hoc, subset
analysis from the phase III trial (EF-11) demonstrated
a higher OS in patients that were treated for 75% or
more of the time (approximately 18 hours per day
on average over the course of a month) compared to
those patients treated for less than 75% of the time
on average (OS 7.8 months v 4.5 months, respec-
tively, P ¼ .04).12DISCUSSION AND CONCLUSIONS
NovoTTF Therapy represents a treatment modality
for rGB that produces effects on multiple phases of the
cell cycle through the use of alternating electric fields
(TTFields). It has undergone clinical comparison with
systemic chemotherapies in a phase III trial in which
NovoTTF Therapy demonstrated a comparable survival
benefit, but with improved patient function in cogni-
tive, social, role, and emotional measures, along with
decreased systemic adverse events such as anorexia,
fatigue, nausea, vomiting.13 A higher OS was seen in
patients that were treated for 75% or more of the time
(approximately 18 hours per day on average over the
course of a month).12 Due to its unique mechanism of
action and the epicutaneous delivery system with
transducer arrays applied on the scalp, dAEs are the
most common adverse events seen with this therapy.
As with any AE, these dAEs can impact the patients’
quality-of-life, adherence to therapy, and medical costs.
A standardized system for clinical description and
grading of dAEs related to NovoTTF Therapy is
critical in order to ensure proper communication
between healthcare providers and to identify appro-
priate interventions. Characterization of the dAEs
observed with NovoTTF Therapy revealed that there
are four types of events that differ clinically and that
require distinct preventive and active management
strategies. These are: (1) irritant contact dermatitis
caused by chemical irritation from sweat, hydrogel,
and/or alcohol; (2) allergic (immunologic) contact
dermatitis resulting from a delayed typehypersensitivity to tape and/or hydrogel; (3) mechan-
ical erosions from cuts induced by shaving and
stripping injury from array removal; (4) ulcers from
decreased perfusion where the ceramic discs com-
press the skin, especially over scars or hardware; and
(5) skin infections that are bacterial in origin. Taken
as a whole, the pathogenic mechanisms underlying
dAEs with NovoTTF Therapy are probably related to
the occlusive nature of the adhesive tape of the
bandages and hydrogel-covered ceramic discs, rather
than to the TTFields generated by the device.
Similar dAEs, including allergic and irritant dermati-
tis, ulcers, and skin infections, have been described
with other devices that are directly applied onto skin,
such as abdominal appliances for stomas and ileal
conduits.48,49 To date, there are no randomized con-
trolled trials for the prevention or management of dAEs
from the use of abdominal appliances, yet there are
abundant anecdotal and empirical data. Indeed, more
than 30% of colostomy patients and more than 70% of
urostomy and ileostomy patients develop dAEs; how-
ever, this unusually high incidence is likely related in
part to the enzymatic activity produced by bacteria in
the urine and stool. Approximately 30% of visits to
stoma nurses are related to skin complications, under-
scoring the importance of dAEs with epicutaneous
devices.50 Consequently, a similar rationale for the
treatment of NovoTTF Therapy-related dAEs has been
devised here.
Correct identification of AEs will dictate specific
therapies towards their treatment and prevention of
recurrence. While most dAEs may be managed with
topical interventions and relocation of the arrays,
preventive strategies are critical in minimizing recurrent
and additional dAEs. For bacterial infections, a swab
culture along with topical or oral antibiotics are
needed. For erosions or abrasions care should be taken
to avoid mechanical trauma and to isolate the lesion
from further injury. For ulcers, it is important to remove
arrays from the site of the ulcer since they may
decreases blood perfusion and interfere with proper
wound care. Due to the relatively protracted processes
of skin proliferation and wound healing, improvement
and resolution of dAEs usually takes at least 7–14 days.
Thus, at a minimum, interventions to treat dAEs must
continue during this time frame. One notable
Table 4. Proposed Grading for Device-Related Dermatologic Adverse Events
Grade Description*
1 Asymptomatic or mild symptoms; topical therapy indicated (eg, antibiotic, corticosteroid).
2 Moderate symptoms AND topical and systemic therapy indicated (eg, antibiotic, corticosteroid);
device application interruption; temporary relocation of device to avoid affected skin areas; or
isolation by dressings of affected areas indicated.
3 Severe or medically signiﬁcant but not immediately life-threatening AND topical and systemic
therapy indicated (eg, antibiotic, corticosteroid); operative intervention indicated;
hospitalization or prolongation of existing hospitalization indicated; device application
interruption indicated.
4 Life-threatening consequences: urgent intervention indicated; device discontinuation indicated.
n A cutaneous device-related dermatologic event is deﬁned as a disorder characterized by dermatitis, skin infection, erosion, or ulcer
related to the noninvasive use of a medical device.
NovoTTF-100A System for recurrent glioblastoma S13exception is the development of ulcerations. Ulcer-
ations involve the dermis and may require surgical
intervention and may demand a longer time to heal
even with appropriate wound care.
Treatment interventions will depend on the type
and the severity of AE. The severity of AEs is defined
by the National Cancer Institute’s CTCAE. At the
time the phase III NovoTTF Therapy trial was
conducted, the CTCAE version 3.0 was used to
describe dAEs. Current and previous iterations of
the CTCAE (versions 3.0 and 4.0) do not adequately
capture the clinical characteristics and management
of NovoTTF Therapy-induced dAE.13 A proposed
grading system based on the CTCAE has been
described here that includes specific terms related
to NovoTTF Therapy-related dAEs (Table 4), includ-
ing the need for device application interruption or
relocation, application of dressings over the affected
skin, and indications for topical or systemic thera-
pies. This system may allow for more consistent
grading in forthcoming trials investigating the effi-
cacy of NovoTTF Therapy, supportive care interven-
tions and daily clinical care.
Most dAEs can be prevented or managed with the
skin care recommendations set forth in this manu-
script. With the increasing adoption of NovoTTF
Therapy for rGB, proper prevention and timely
management of dAEs is crucial to maintain patient
quality-of-life, to ensure consistent use of the device,
and to maximize the clinical benefit of NovoTTF
Therapy for patients with rGB.REFERENCES
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